Literature DB >> 28936369

Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions.

Jorge R Miranda-Massari1,2,3, José R Rodríguez-Gómez4,5, Michael J González6, Carlos Cidre7, Jorge Duconge8, Heriberto Marín9, Kazuko Grace2, Howard L McLeod10,11.   

Abstract

Diabetes is a leading cause of mortality and morbidity worldwide. Diabetes complications produce profound impact on patient's quality of life and represent very significant economic cost to patients, their family, the government and society as a whole. Metabolic correction has been proposed as an efficient method to improve clinical outcomes and reduce costs in diabetes. Metabolic correction is a concept that supports health maintenance and promotes the healing processes by improving the body's biochemical-physiological mechanisms. This is done by helping activate the metabolic enzymes necessary to facilitate key physiological pathways. A group of 50 patients followed a simple metabolic correction strategy based on hydration, diet, and magnesium supplementation during a 6 months period. Outcomes measures included laboratory testing, anthropometric measures and medication use including its related costs. Patients had an average weight loss of 9.4 lbs (↓5.0%) from baseline at month 3 and 12 lbs (↓6.4%) at month 6. Waist circumference decreased on average 3.7 inches (↓9.0%) from baseline at month 3 and had further decrease to 5.5 inches (↓13.4%) from baseline at month 6. Laboratory testing of average triglycerides decreased from a baseline of 156.9 to 116.7 (↓25.6%) at month 3 and maintained a reduction of ↓24.2% by month 6. Total cholesterol concentration decreased from a baseline of 181.1 mg/dL to 173.9 (↓4.0%) in month 3 and to 171.1 (↓5.5%) at month 6. Average HgA1c decreased from baseline of 7.17 to 6.52 (↓9.1%) at month 3 and maintained 6.52 at months 6. The atherogenic index decreased from 4.18 at baseline to 3.85 at month 3 (↓7.9%) and then 3.47 (17.0%) at month 6. Medication use and cost was quantified in various ways. The average baseline monthly diabetes medication cost per patient of $124.10 was reduced to $ 78.23 (↓36.7% reduction) at month 3 and to $62.80 (↓49.4% reduction) at month 6. A simple and well structured metabolic correction program that includes a significant educational component, dietary modifications and dietary supplement intake was able to maintain or improve vital signs, anthopometric and laboratory measurements that correlate with improved clinical diabetes and cardiovascular health. This outcome was achieved while decreasing the use medications at month 3 and 6 at significant cost savings.

Entities:  

Keywords:  Cost reduction; Diabetes; Diabetes care cost; Diet; Magnesium; Magnesium supplementation; Metabolic Correction

Year:  2016        PMID: 28936369      PMCID: PMC5604848     

Source DB:  PubMed          Journal:  Int J Diabetes Res


  80 in total

Review 1.  Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease.

Authors:  Prakash C Deedwania
Journal:  Am J Cardiol       Date:  2003-01-01       Impact factor: 2.778

Review 2.  Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance.

Authors:  Mario Barbagallo; Ligia J Dominguez
Journal:  Arch Biochem Biophys       Date:  2006-06-12       Impact factor: 4.013

3.  Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria.

Authors:  M Schütt; W Kern; U Krause; P Busch; A Dapp; R Grziwotz; I Mayer; J Rosenbauer; C Wagner; A Zimmermann; W Kerner; R W Holl
Journal:  Exp Clin Endocrinol Diabetes       Date:  2006-07       Impact factor: 2.949

4.  Diabetes-related nutrition knowledge and dietary intake among adults with type 2 diabetes.

Authors:  Cathy Breen; Miriam Ryan; Michael J Gibney; Donal O'Shea
Journal:  Br J Nutr       Date:  2015-07-14       Impact factor: 3.718

Review 5.  Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.

Authors:  Molly C Carr; John D Brunzell
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

6.  Experience of knowledge and skills that are essential in self-managing a chronic condition - a focus group study among people with type 2 diabetes.

Authors:  Ann Jorunn Herre; Marit Graue; Beate-Christin Hope Kolltveit; Eva Gjengedal
Journal:  Scand J Caring Sci       Date:  2015-08-12

Review 7.  Economic costs of diabetes in the U.S. In 2007.

Authors: 
Journal:  Diabetes Care       Date:  2008-03       Impact factor: 19.112

8.  Sympathetic nervous system-dependent vasoconstriction in humans. Evidence for mechanistic role of endogenous purine compounds.

Authors:  S Taddei; R Pedrinelli; A Salvetti
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

Review 9.  The role of magnesium in hypertension and cardiovascular disease.

Authors:  Mark Houston
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-09-26       Impact factor: 3.738

10.  Cross-sectional associations between measures of sleep and markers of glucose metabolism among subjects with and without diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Sleep Study.

Authors:  Kristen L Knutson; Eve Van Cauter; Phyllis Zee; Kiang Liu; Diane S Lauderdale
Journal:  Diabetes Care       Date:  2011-03-16       Impact factor: 19.112

View more
  2 in total

1.  Economic burden of diabetes among medicare beneficiaries with cancer.

Authors:  Cassidi C McDaniel; F Ellen Loh; Devan M Rockwell; Courtney P McDonald; Chiahung Chou
Journal:  J Pharm Health Serv Res       Date:  2021-03-06

2.  Oscillatory pattern of glycemic control in patients with diabetes mellitus.

Authors:  Manuel Vasquez-Muñoz; Alexis Arce-Alvarez; Magdalena von Igel; Carlos Veliz; Gonzalo Ruiz-Esquide; Rodrigo Ramirez-Campillo; Cristian Alvarez; Robinson Ramirez-Velez; Fernando A Crespo; Mikel Izquierdo; Rodrigo Del Rio; David C Andrade
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.